Hims & Hers Health, Inc. logo

Hims & Hers Health, Inc. (HIMS)

Market Open
5 Jun, 16:56
NYSE NYSE
$
25. 93
-2.08
-7.4259%
$
5.66B Market Cap
- P/E Ratio
- Div Yield
9.73M Volume
-0.14 Eps
$ 28.01
Previous Close
Add Transaction
Day Range
25.69 27.89
Year Range
13.74 70.43
Want to track HIMS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
HIMS Stock Declines Following Q4 Earnings Miss, Gross Margin Contracts

HIMS Stock Declines Following Q4 Earnings Miss, Gross Margin Contracts

Hims & Hers' revenue channels witness strong growth on the back of solid product demand in the fourth quarter.

Zacks | 1 year ago
Hims Stock Crashed After Earnings. What Went Wrong?

Hims Stock Crashed After Earnings. What Went Wrong?

In this video, I will go over the fourth-quarter earnings report from Hims & Hers (HIMS -27.60%) and explain why the stock crashed on Tuesday. Watch the short video to learn more, consider subscribing, and click the special offer link below.

Fool | 1 year ago
Hims & Hers Stock Crashed 26% Today. Here's What You Need to Know

Hims & Hers Stock Crashed 26% Today. Here's What You Need to Know

Hims & Hers (HIMS -27.66%) continues to grow at an astounding rate as the company grows subscribers and revenue per subscriber. But Hims & Hers stock is falling after earnings because investors are concerned about the future of GLP-1s.

Fool | 1 year ago
Hims & Hers shares plunge 28% on concerns over weight loss business, margins

Hims & Hers shares plunge 28% on concerns over weight loss business, margins

Hims & Hers shares fell on Tuesday, a day after the company released fourth-quarter results that disappointed on gross margin and outlined changes to its weight loss business. The company reported $481 million in revenue for the quarter, up 95% from $246.6 million during the same period last year.

Cnbc | 1 year ago
Hims & Hers CFO talks Q4 earnings

Hims & Hers CFO talks Q4 earnings

Hims & Hers Health (HIMS) stock is dropping in extended hours upon the telehealth company's fourth quarter earnings release, topping revenue ($481.14 million vs. forecasts of $470.39 million) and total subscribers estimates (2.23 million vs.

Youtube | 1 year ago
Novo Nordisk's stock is rallying as Hims & Hers' stock falters. An Ozempic alternative won't be available for long.

Novo Nordisk's stock is rallying as Hims & Hers' stock falters. An Ozempic alternative won't be available for long.

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won't be selling it for much longer.

Marketwatch | 1 year ago
Hims & Hers shares drop on doubts over weight-loss business forecast

Hims & Hers shares drop on doubts over weight-loss business forecast

Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's lofty sales forecast in the face of looming restrictions on compounded weight-loss drugs.

Reuters | 1 year ago
Hims & Hers Earnings: Very Strong Business, In A Very Crowded Trade

Hims & Hers Earnings: Very Strong Business, In A Very Crowded Trade

Hims & Hers experienced a sell-off due to profit-taking and weaker-than-expected EBITDA margins, despite strong revenue growth. The company is projected to generate over $2 billion in revenues and $350 million in free cash flow in 2025, with no debt. While EBITDA margins have fluctuated, free cash flow remains strong, making the stock attractive at 26x forward free cash flow.

Seekingalpha | 1 year ago
Hims & Hers: Why This Q4 Earnings Dip Is A Buying Opportunity

Hims & Hers: Why This Q4 Earnings Dip Is A Buying Opportunity

Hims & Hers stock fell ~19% post-Q4 earnings despite revenue beating expectations and EPS aligning with estimates, attributed to gross margin concerns and potential dependency on GLP-1 for future growth. The company's growth remains strong, with a 95% YoY revenue increase, an expanding subscriber base, and higher revenue per subscriber, indicating robust market capture and customer loyalty. Future potential is promising with new service additions, a vast addressable market, and strategic diversification, mitigating risks from competition and regulatory changes.

Seekingalpha | 1 year ago
Hims & Hers CFO, drone regulation: Asking for a Trend

Hims & Hers CFO, drone regulation: Asking for a Trend

Josh Lipton takes a closer look at the top stories investors need to know after the closing bell on Asking for a Trend. Hims & Hers Health (HIMS) CFO Yemi Okupe breaks down the quarterly results as shares plunge following the report.

Youtube | 1 year ago
Hims & Hers: Post Earnings Drop Is Very Welcomed

Hims & Hers: Post Earnings Drop Is Very Welcomed

Hims & Hers reported a double beat with Q4 revenue at $481M, a 95% YoY improvement, but faced an 18% stock drop after hours. Despite margin contraction due to new weight loss offerings, adjusted EBITDA increased 163% YoY, highlighting long-term growth potential. Management's goal of 10 million subscribers in 5–6 years, with AI integration and Trybe Labs acquisition, presents a bullish opportunity.

Seekingalpha | 1 year ago
Compared to Estimates, Hims & Hers Health (HIMS) Q4 Earnings: A Look at Key Metrics

Compared to Estimates, Hims & Hers Health (HIMS) Q4 Earnings: A Look at Key Metrics

Although the revenue and EPS for Hims & Hers Health (HIMS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 1 year ago
Loading...
Load More